We advance human health and well-being by providing an extensive portfolio of in-vitro diagnostic (IVD) systems, reagent kits, and software used by thousands of hospitals and laboratories worldwide. Most notably, Waters delivers technologies for newborn screening, an area of clinical diagnostics that has made a healthy adult life possible for millions.
It was to be my third outing to the Association of Public Health Laboratories (APHL) Newborn Screening and Genetic Testing Symposium (NBSGTS), this being the 27th meeting of its kind, bringing some 500 members of the screening and genetics community to the jewel of Lake Michigan, The Windy City, The City With Big Shoulders, Chi-Town:…
Newborn screening for inherited disorders has been heralded as one of the 10 greatest public health achievements of the first decade of the 21st century.1 The ability to pre-symptomatically identify newborn babies at risk of developing endocrine, hematologic, and metabolic disorders has dramatically improved or saved thousands of lives (and saved the healthcare system millions…
We perform a study using Symphony Data Pipeline software in combination with Elucidata’s MSConvert and EIMaven to automate data processing in the comparison of 2D and 3D in vitro cultures in non-small-cell lung carcinoma.
Don Mason reviews the state of newborn screening (NBS) programs around the world.
Reflecting on a common concern in newborn screening: Reliability.
Waters’ legacy of purposeful innovation continues with the recently introduced RenataDX Screening System, a flow-injection tandem mass spectrometry system for high-throughput analysis of extracted dried blood spots and other physiological matrices.
Newborn screening for inherited metabolic disorders dates to the early 1960s when Dr. Robert Guthrie in Buffalo, New York developed the first screening test for phenylketonuria (or PKU), a metabolic disease in which patients can’t metabolize the amino acid phenylalanine.
Mass spectrometry has been game changer in newborn screening because rather than having a single test for a single condition, there was now a technique that provided a single test for a large number of different conditions.
Q&A from a recent forensic toxicology webinar on using an ACQUITY UPLC I-Class/Xevo TQ-S micro MS system for quantifying cannabinoids in oral fluid.
Meet Vicky, who joined Waters’ Customer Success Team about two years ago with 20 years of LC-MS experience. She specializes in clinical forensic and toxicological applications supporting customers in Northern Europe.
Eradicating all the mosquitoes that may cause Dengue fever isn’t a realistic solution. Instead, researchers at the NUS are using advanced analytical technologies to understand what causes the virus to incubate and spread – and thus, to find a way to stop it.
Labs like King’s Liver Laboratories in London need to analyze thousands of samples with fast turnaround times, so it’s critical to have reliable LC-MS/MS instrumentation that works every day and provides accurate and precise results.